Literature DB >> 21123096

Zoledronate inhibits intimal hyperplasia in balloon-injured rat carotid artery.

L Wu1, L Zhu, W H Shi, B Yu, D Cai.   

Abstract

BACKGROUND AND
OBJECTIVE: Zoledronate has been reported to inhibit the proliferation, adhesion and migration of vascular smooth muscle cells. In the present study, we assessed whether systemic and local delivery of zoledronate would be sufficient to prevent intimal hyperplasia.
METHODS: Twenty-four male Sprague-Dawley rats were assigned into four groups: non-treated group, systemic zoledronate-treated group, local collagen-treated group and local zoledronate-treated group. All four groups underwent balloon injury to the right common carotid artery. The left uninjured carotid arteries of the non-treated group were considered as normal artery samples. Twenty-one days after arterial injury and treatment, the right and left common carotid arteries were fixed, sectioned, stained and measured by computer-aided image analysis.
RESULTS: At 3 weeks, there was a 59% reduction of the intima/media area ratio in the systemic zoledronate-treated group compared with the non-treated group (P < 0.01). There was an 87% reduction of the intima/media area ratio in the local zoledronate-treated group compared with the local collagen-treated group (P < 0.01).
CONCLUSIONS: Both systemic and local delivery of zoledronate correspond to a significant reduction in intimal hyperplasia seen at 3 weeks.
Copyright © 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123096     DOI: 10.1016/j.ejvs.2010.07.028

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  4 in total

1.  20-Hydroxyeicosatetraenoic acid inhibition attenuates balloon injury-induced neointima formation and vascular remodeling in rat carotid arteries.

Authors:  Ludwig D Orozco; Huiling Liu; Eddie Perkins; Daryl A Johnson; Betty B Chen; Fan Fan; Rodney C Baker; Richard J Roman
Journal:  J Pharmacol Exp Ther       Date:  2013-05-08       Impact factor: 4.030

2.  Differential effect of zoledronic acid on human vascular smooth muscle cells.

Authors:  Hassan Albadawi; Mounir J Haurani; Rahmi Oklu; Jordan P Trubiano; Peter J Laub; Hyung-Jin Yoo; Michael T Watkins
Journal:  J Surg Res       Date:  2012-11-08       Impact factor: 2.192

3.  Zoledronate alters natural progression of tissue-engineered vascular grafts.

Authors:  Yu-Chun Chang; Junlang Li; Gabriel Mirhaidari; Jacob Zbinden; Jenny Barker; Kevin Blum; James Reinhardt; Cameron Best; John Kelly; Toshihiro Shoji; Tai Yi; Christopher Breuer
Journal:  FASEB J       Date:  2021-10       Impact factor: 5.834

4.  Zoledronate inhibits fibroblasts' proliferation and activation via targeting TGF-β signaling pathway.

Authors:  Zichang Zhao; Wei Shen; Hanbin Zhu; Lin Lin; Gening Jiang; Yongzhe Zhu; Hongyuan Song; Liang Wu
Journal:  Drug Des Devel Ther       Date:  2018-09-17       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.